Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis

doi:10.3748/wjg.v22.i33.7579

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 33

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8373)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-8) series.

Item

Count

PDF

511

WORD

325

HTML

3958

Figures (1-2)

264

Tables (1-8)

244

Sum=5302

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1046

Download

2025

Sum=3071

Sep 7, 2016 (publication date) through Dec 21, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Sep 7, 2016; 22(33): 7579-7586
Published online Sep 7, 2016. doi: 10.3748/wjg.v22.i33.7579

Table 7 Comparison of autoantibodies between typed drug-induced liver injury and primary biliary cirrhosis patients n (%)

	Autoantibodies	ANA	AMA	SMA	AMA-M2	AMA-M4	AMA-M9
Hepatocellular type DILI (n = 90)	43 (47.7)^a	41 (45.5)^a	2 (2.22)^a	2 (2.22)	2 (2.22)^a	0^a	1 (1.11)^a
Cholestatic type DILI (n = 20)	10 (50.0)^a	8 (40.0)^a	2 (10.0)^a	1 (5.00)	1 (5.00)^a	0^a	1 (5.00)
Mixed type DILI (n = 14)	6 (42.8)^a	6 (42.8)^a	0^a	1 (7.14)	0^a	1 (7.14)	1 (7.14)
PBC (n = 116)	106 (91.3)	98 (84.4)	98 (84.4)	2 (1.72)	98 (84.4)	34 (29.3)	19 (16.3)

^aP < 0.05 vs the PBC group. DILI: Drug-induced liver injury; PBC: Primary biliary cirrhosis; ANA: Antinuclear antibody; AMA: Antimitochondrial antibody; SMA: Anti-smooth muscle antibody.

Citation: Yang J, Yu YL, Jin Y, Zhang Y, Zheng CQ. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. World J Gastroenterol 2016; 22(33): 7579-7586
URL: https://www.wjgnet.com/1007-9327/full/v22/i33/7579.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i33.7579